Sales & Marketing News | pharmaphorum

News

Vice President Kamala Harris and President Joe Biden in conversation

Biden, Harris 'just getting started' on IRA drug price cuts

In their first joint appearance since Joe Biden withdrew from the Presidential race to be replaced on the Democrat ticket by Kamala Harris, the duo celebrated the long sought-after Medicare

News

medicines and dollars - the price of prescription drugs

IRA negotiated prices revealed as Biden claims $6bn savings

The US government has published the finalised 'maximum fair prices' (MFPs) for the first 10 medicines subject to Medicare negotiations under the Inflation Reduction Act (IRA), shortly after

News

PBC drug choices rise in US with OK for Gilead's seladelpar

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade.

News

Incyte builds GvHD presence with Niktimvo approval

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.

News

Rachel Reeves appointed as Chancellor of the Exchequer by Keir Starmer, 5th July 2024

AstraZeneca said to be wavering on £450m UK vaccine plant

AstraZeneca's plan to invest £450 million ($578 million) in a vaccines manufacturing plant in the UK has been thrown into doubt, claims a report in the Financial Times.

News

dialysis machine at patient hospital bedside

Baxter slims down again, selling kidney division to Carlyle

Baxter International has agreed to sell its kidney treatment division to private equity firm Carlyle Group in a $3.8 billion cash deal, continuing its efforts to streamline its operations a

Biden, Harris 'just getting started' on IRA drug price cuts

IRA negotiated prices revealed as Biden claims $6bn savings

PBC drug choices rise in US with OK for Gilead's seladelpar

Incyte builds GvHD presence with Niktimvo approval

AstraZeneca said to be wavering on £450m UK vaccine plant

Baxter slims down again, selling kidney division to Carlyle

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks